Tech Company Financing Transactions
Solu Therapeutics Funding Round
On 4/9/2025, Solu Therapeutics received $41 million in Series A funding from Alexandria Venture Investments, Astellas Venture Capital and Biovision Ventures.
Transaction Overview
Company Name
Announced On
4/9/2025
Transaction Type
Venture Equity
Amount
$41,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to complete dose escalation and expand its lead CCR2-CyTAC program, STX-0712, for the treatment of CMML.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Boston, MA Undisclosed
USA
Boston, MA Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Overview
Solu Therapeutics is a precision-medicine company developing therapeutics to eliminate disease-driving cells. Solu Therapeutics, a precision-medicine company, is developing therapeutics to eliminate disease-driving cells in cancer, immunology, and autoimmunity. The proprietary CyTaC (Cytotoxicity Targeting Chimera) platform and drug candidates, licensed from GSK, unlock antibody-intractable cell surface targets providing the capability to develop next generation medicines that harness the power of biologics with the vast target binding space of small molecules. Unique characteristics of CyTaC platform molecules include: (i) unlocking new tumor-associated antigens to eliminate cancer cells, (ii) depleting pathogenic immune cells, and (iii) extending the half-life of small molecule antagonists and agonists.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Donabedian
Chief Medical Officer
Ewelina Morawa
Co-Founder
Brandon Turunen
Browse more venture capital transactions:
Prev: 4/9/2025: Daedalus Industrial venture capital transaction
Next: 4/9/2025: NOWOS venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to report on every notable VC transaction. VC investment data records on this site come from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs